BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23729692)

  • 1. Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke.
    Kim D; Lee SH; Joon Kim B; Jung KH; Yu KH; Lee BC; Roh JK;
    Eur Heart J; 2013 Sep; 34(35):2760-7. PubMed ID: 23729692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy as a modulator of stroke aetiology: a meta-analysis.
    Rajkumar CA; Floyd CN; Ferro A
    Br J Clin Pharmacol; 2015 Sep; 80(3):331-41. PubMed ID: 25784356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke subtypes and interventional studies for transient ischemic attack.
    Lavallée P; Amarenco P
    Front Neurol Neurosci; 2014; 33():135-46. PubMed ID: 24157562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient atrial fibrillation and risk of stroke after acute myocardial infarction.
    Bishara R; Telman G; Bahouth F; Lessick J; Aronson D
    Thromb Haemost; 2011 Nov; 106(5):877-84. PubMed ID: 21866303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack.
    Davis SM; Donnan GA
    N Engl J Med; 2012 May; 366(20):1914-22. PubMed ID: 22591297
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiplatelet, anticoagulant and fibrinolytic agents in acute ischaemic stroke and TIA.
    Sandercock P; Lindley R; Wardlaw J
    Br J Hosp Med; 1992 May 20-Jun 2; 47(10):731-7. PubMed ID: 1606457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
    Diener HC; Weber R; Weimar C; Röther J
    Int J Clin Pract; 2011 May; 65(5):531-5. PubMed ID: 21489077
    [No Abstract]   [Full Text] [Related]  

  • 8. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]).
    Schwammenthal Y; Bornstein N; Schwammenthal E; Schwartz R; Goldbourt U; Tsabari R; Koton S; Grossman E; Tanne D
    Am J Cardiol; 2010 Feb; 105(3):411-6. PubMed ID: 20102959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke.
    Weber R; Weimar C; Diener HC
    Expert Opin Pharmacother; 2009 Aug; 10(12):1883-94. PubMed ID: 19558342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
    Aw D; Sharma JC
    Postgrad Med J; 2012 Jan; 88(1035):34-7. PubMed ID: 22121248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filling the gap between science & clinical practice: prevention of stroke recurrence.
    Russolillo A; Di Minno MN; Tufano A; Prisco D; Di Minno G
    Thromb Res; 2012 Jan; 129(1):3-8. PubMed ID: 21907395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic management of ischaemic stroke and transient ischaemic attack in China: a consecutive cross-sectional survey.
    Wang YL; Wu D; Nguyen-Huynh MN; Zhou Y; Wang CX; Zhao XQ; Liao XL; Liu LP; Wang YJ;
    Clin Exp Pharmacol Physiol; 2010 Aug; 37(8):775-81. PubMed ID: 20456429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of oral anticoagulation after acute ischaemic stroke or transient ischaemic attack: timing and complications of overlapping heparin or conventional treatment.
    Audebert HJ; Schenk B; Tietz V; Schenkel J; Heuschmann PU
    Cerebrovasc Dis; 2008; 26(2):171-7. PubMed ID: 18628615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
    Hankey GJ
    Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiplatelet therapy: update in secondary stroke prevention].
    Uchiyama S
    Brain Nerve; 2013 Jul; 65(7):771-82. PubMed ID: 23832980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in antiplatelet use prior to incident ischaemic stroke over 7 years in a UK centre and the association with stroke subtype.
    White JR; Bettencourt-Silva JH; Potter JF; Loke YK; Myint PK
    Age Ageing; 2013 Sep; 42(5):594-8. PubMed ID: 23832263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPiS trial.
    Doehner W; Schenkel J; Anker SD; Springer J; Audebert HJ
    Eur Heart J; 2013 Jan; 34(4):268-77. PubMed ID: 23076781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antithrombotic therapy in the secondary prevention of stroke].
    Mel'nikova EV; Kadinskaia MI; Gerasimenko DV; Shmonin AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12 Pt 2):23-7. PubMed ID: 21626814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study.
    Tsivgoulis G; Spengos K; Zakopoulos N; Manios E; Peppes V; Vemmos K
    Age Ageing; 2005 Jan; 34(1):35-40. PubMed ID: 15591481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.